Seattle based Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases

Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that pharma companies experienced in the past. He explains how the company is currently putting it to use in cirrhosis, liver failure (with partner Genfit), and in CNS conditions (along with LRRK2).